Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Amed Co., Ltd. (7575:TWSE), powered by AI.
Amed Co., Ltd. is currently trading at $18.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Amed Co., Ltd. on Alpha Lenz.
View Amed Co., Ltd.'s valuation metrics on Alpha Lenz.
“Amed Co., Ltd.'s ROE is 8.9%. Explore profitability and growth together.”
Ask for details →Amed Co., Ltd. is a healthcare company specializing in the research, development, manufacturing, and distribution of medical equipment and consumables. Founded in 2008 and headquartered in New Taipei City, Taiwan, the company operates through three core business platforms: wound care, pain-free medical solutions, and medical device support. Its wound care platform delivers advanced solutions such as high-end wound dressings under the HERADERM brand and negative pressure wound therapy systems, addressing a broad spectrum of wound management needs. The pain-free medical platform provides long-acting pain relief products, including 7-day injectable formulations like those marketed under the Naldebain brand, facilitating smoother post-operative recovery. The medical device support platform encompasses innovative tools such as implantable port kits and artificial blood vessels, designed to simplify clinical procedures and support healthcare providers. Amed Co., Ltd.’s portfolio is distributed both domestically and internationally, contributing to sectors such as hospitals, clinics, and specialist medical settings. With an emphasis on innovation and quality, the company plays a notable role in the medical instruments and supplies industry, serving the growing demands of modern healthcare systems.
“Amed Co., Ltd.'s ROE is 8.9%. Explore profitability and growth together.”
Ask for details →Amed Co., Ltd. (ticker: 7575) is a company listed on TWSE in the Healthcare sector (Medical Instruments & Supplies).
The current price is 18.4 with a P/E ratio of -x and P/B of -x.
ROE is 8.91% and operating margin is 9.29%. Annual revenue is $822M.